1.Advances in telecare in the management of medication adherence in post-PCI patients: a review
Yang GE ; Xueqing ZHU ; Chaokai HE ; Ye ZHANG ; Sheng YUAN ; Jingjing WANG
Chinese Journal of Practical Nursing 2024;40(27):2150-2155
Telecare technology has facilitated the close integration of information technology and healthcare services. Currently, telecare technology is widely used in different fields to assist caregivers in the behavioural management and monitoring of medication adherence in post-PCI patients, to safeguard therapeutic outcomes and to reduce the incidence of adverse events. This article mainly reviewed the different telecare intervention models for medication adherence in post-PCI patients in China and abroad, the effect of telecare in medication adherence management, as well as shortcomings and prospects. The aim of this review was to understand the current status of the application of telecare in the management of medication adherence in post-PCI patients and to provide new ideas to improve the management of medication adherence in post-PCI patients.
2.Xixintang-medicated Serum Regulates Aβ25-35-induced Polarization of BV-2 Microglial Cells
Chaokai YANG ; Yongchang DIWU ; Yangyang WU ; Xia XING ; Dengkun WANG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(6):18-26
ObjectiveTo investigate the effects of Xixintang (XXT)-medicated serum on the amyloid β-protein (Aβ)25-35-induced polarization of BV-2 microglial cells by a cell experiment and uncover the potential mechanisms of this formula in the prevention and treatment of Alzheimer's disease (AD), thus providing scientific evidence for the clinical application of XXT. MethodsBV-2 microglial cells were subcultured. The optimal concentrations of XXT-medicated serum and Aβ25-35 were determined via the cell-counting kit-8 (CCK-8) assay. The cell experiment was carried out with the following groups: blank control, model (Aβ25-35 at 40 μmol·L-1), XXT-medicated serum (Aβ25-35 at 40 μmol·L-1 + 10% XXT-medicated serum), and blank serum (Aβ25-35 at 40 μmol·L-1 + 10% blank serum). After 24 hours of cell incubation, immunofluorescence was used to detect the expression of ionized calcium-binding adaptor molecule 1 (IBA1), CD16/32, and CD206. Real-time PCR was performed to measure the mRNA levels of CD206, CD163, inducible nitric oxide synthase (iNOS), and arginase 1 (Arg-1). Enzyme-linked immunosorbent assay (ELISA) was employed to quantify the levels of nerve growth factor (NGF), iNOS, and Arg-1. The nitric oxide (NO) concentration was determined via the nitrate reductase method. ResultsCompared with the blank control group, the model group showed increased expression of IBA1 and CD16/32 (P<0.01), decreased expression of CD206 (P<0.05), upregulation in the mRNA level (P<0.01) and content (P<0.05) of iNOS, downregulation in the mRNA levels of CD206, CD163, and Arg-1 (P<0.05, P<0.01), lowered levels of Arg-1 and NGF (P<0.05), and an elevation in the NO level (P<0.05). Compared with the model group, the XXT-medicated serum group exhibited reduced expression of IBA1 and CD16/32 (P<0.05, P<0.01) and increased expression of CD206 (P<0.01). Both the content and mRNA level of iNOS were downregulated (P<0.05, P<0.01), while the mRNA levels of CD206, CD163, and Arg-1 were upregulated (P<0.01) in the XXT-medicated serum group. In addition, the XXT-medicated serum group showed elevated levels of Arg-1 and NGF (P<0.05) and a lowered level of NO (P<0.05). The blank serum group showed no statistically significant differences in the measured parameters compared with the model group. ConclusionThe XXT-medicated serum can inhibit the polarization toward the M1 phenotype and promote the polarization toward the M2 phenotype, exerting anti-inflammatory and neurotrophic effects.